A concern was expressed about a distributor for BTM having its own competitor product.
But all of the info about those products and the partner was available to PolyNovo before it entered into the relationship.
My point is that if the initially expressed worry is genuine then the worrier must have an even bigger worry about the capacity of the company to make sound business decisions.
But all the evidence suggests that the chair, board, and executive team is knowledgeable and highly effective.
So, the initial worry is ill-founded or malicious.
The Clinicians Speak, page-813
-
- There are more pages in this discussion • 221 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.61 |
Change
0.090(3.57%) |
Mkt cap ! $1.801B | |||
| Open | High | Low | Value | Volume |
| $2.59 | $2.66 | $2.58 | $3.183M | 1.217M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19229 | $2.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.62 | 3084 | 2 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |